Skip to content
Home/Companies/Healthcare/SERB Pharmaceuticals
SERB Pharmaceuticals

SERB Pharmaceuticals

Healthcare·Belgium·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns SERB Pharmaceuticals?

SERB Pharmaceuticals is currently owned by Merieux Equity Partners through Mérieux Participations 3 (2019 vintage), since 2021.

Hand-verified · updated 2026-05-07

Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Participations 3 · 2019 · Buyout

Key facts

HQEurope
SectorHealthcare
StatusActive
Websiteserb.com

More from Mérieux Participations 3

Other portfolio companies in the same fund.

Ceva Sante Animale
Ceva Sante Animale
Active
HealthcareFrance
Janvier Labs
Janvier Labs
Active
HealthcareFrance· 2022
Dental Monitoring
Dental Monitoring
Active
HealthTechFrance· 2021
Domus VI
Domus VI
Active
HealthcareFrance· 2021
DomusVi
DomusVi
Active
HealthcareFrance· 2021
SWIXX BioPharma
SWIXX BioPharma
Exited 2026
HealthcareSwitzerland· 2021
to

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Acentra Health
Acentra Health
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Track SERB Pharmaceuticals

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy SERB Pharmaceuticals?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on SERB Pharmaceuticals.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue